Childhood Asthma: Treatment Update
Am Fam Physician. 2005 May 15;71(10):1959-1968.
Patient information: See related handout on treatment of childhood asthma, written by the authors of this article.
This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). EB CME is clinical content presented with practice recommendations supported by evidence that has been systematically reviewed by an AAFP-approved source.
The prevalence of childhood asthma has risen significantly over the past four decades. A family history of atopic disease is associated with an increased likelihood of developing asthma, and environmental triggers such as tobacco smoke significantly increase the severity of daily asthma symptoms and the frequency of acute exacerbations. The goal of asthma therapy is to control symptoms, optimize lung function, and minimize days lost from school. Acute care of an asthma exacerbation involves the use of inhaled beta2 agonists delivered by a metered-dose inhaler with a spacer, or a nebulizer, supplemented by anticholinergics in more severe exacerbations. The use of systemic and inhaled corticosteroids early in an asthma attack may decrease the rate of hospitalization. Chronic care focuses on controlling asthma by treating the underlying airway inflammation. Inhaled corticosteroids are the agent of choice in preventive care, but leukotriene inhibitors and nedocromil also can be used as prophylactic therapy. Long-acting beta2 agonists may be added to one of the anti-inflammatory medications to improve control of asthma symptoms. Education programs for caregivers and self-management training for children with asthma improve outcomes. Although the control of allergens has not been demonstrated to work as monotherapy, immunotherapy as an adjunct to standard medical therapy can improve asthma control. Sublingual immunotherapy is a newer, more convenient option than injectable immunotherapy, but it requires further study. Omalizumab, a newer medication for prevention and control of moderate to severe asthma, is an expensive option.
Asthma is a chronic lung disease characterized by recurrent cough and wheeze that is increasing in prevalence among children. More than 5 percent of the U.S. population younger than 18 years—nearly 5 million children—is affected by this disorder. It is found more often in patients with a personal or family history of atopy.1 This article summarizes the treatment of asthma in children, with an emphasis on new modalities and the results of recent studies.
Development of Asthma
The development of asthma in children is thought to be the final step in a disease process described as the “allergic march.” The allergic march may begin in infancy with food allergy–associated gastrointestinal disorders and dermatitis. Allergic rhinoconjunctivitis follows in early childhood, and asthma often completes the picture.2 Early atopic dermatitis and elevated serum IgE antibodies against food allergens within the first two years of life, combined with family history, can be used to predict aeroallergen sensitization at five years of age.3 Recent data from randomized controlled trials (RCTs) have suggested that early use of some antihistamines or immunotherapy may reduce the number of children who progress from rhinoconjunctivitis to asthma.4,5
Strength of Recommendations
Strength of Recommendations
|Key clinical recommendation||Label||References|
A spacer with a metered-dose inhaler is as effective as a nebulizer for delivery of a bronchodilator in the treatment of an acute asthma exacerbation and for the delivery of chronic prophylactic medications.
Physicians should consider adding inhaled ipratropium bromide (Atrovent) with each inhalation of a beta2 agonist, particularly in the treatment of a more severe asthma exacerbation.
If possible, oral corticosteroids should be administered within 45 minutes of the onset of symptoms in an acute asthma exacerbation.
Modest doses of an inhaled corticosteroid are more effective than inhaled long-acting beta2 agonists, inhaled nedocromil (Tilade), and leukotriene inhibitors in improving asthma symptoms and lung function in children with moderate persistent asthma and are recommended as the first-line treatment.
Parents and caregivers of children with asthma, particularly those with moderate to severe disease, should be taught to recognize and avoid triggers and to understand the use of prescribed medications and inhalation devices, and the importance of compliance and monitoring.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 1865 for more information.
Asthma causes airway hyperresponsiveness, airflow limitation, and persistent respiratory symptoms such as wheezing, coughing, chest tightness, and shortness of breath. The majority of children with asthma develop symptoms before five years of age.1 Because the symptoms vary extensively, asthma must be distinguished from other causes of respiratory illness. Demonstrating reversible airway obstruction in children old enough to perform peak flow measurements or spirometry provides an objective means of confirming the diagnosis. Once a child is diagnosed with asthma, the goal of therapy is to reduce wheeze and cough, reduce the risk and number of acute exacerbations, and minimize adverse effects of treatments, sleep disturbances, and absences from school.6 Treatment is tailored to the severity of asthma. The standard classification of asthma severity from the National Institutes of Health consensus guideline is shown in Table 1.7
TABLE 1 Long-Term Management of Asthma in Children
Long-Term Management of Asthma in Children
|Asthma classification*||Symptom frequency||Lung function†||Medications required to maintain long-term control|
Daytime: 2 days per week or less
PEF or FEV1: 80 percent or more of predicted function
Nighttime: 2 nights per month or less
Daytime: more than 2 days per week, but less than 1 time per day
PEF or FEV1: 80 percent or more of predicted function
Nighttime: more than 2 nights per month
PEF or FEV1: 60 to 80 percent of predicted function
Nighttime: more than 1 night per week
PEF or FEV1: 60 percent or less of predicted function
PEF = peak expiratory flow; FEV1 = forced expiratory volume in one second.
*—Clinical features before treatment or adequate control.
†—Lung function measurements are used only in patients older than five years.
Adapted from National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics, 2002. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003; NIH publication no. 02–5074:115.
In an acute asthma exacerbation, inhaled beta2 agonists are a mainstay of treatment (Table 2).7 Administration of an inhaled beta2 agonist via a metered-dose inhaler with a spacer device is equally as effective as nebulized therapy.8 There is no evidence to support the use of oral or intravenous beta2 agonists in the treatment of acute asthma.9 There is some evidence that high-dose nebulized beta2 agonists (0.15 mg per kg per dose, approximately six puffs for a 35-kg [77-lb] child) administered every 20 minutes for six doses may be more effective than low-dose beta2 agonists (0.05 mg per kg per dose, approximately two puffs for a 35-kg child) in treating severe acute asthma in children.10 Levalbuterol (Xopenex), the nebulized levo-isomer of albuterol (Proventil), was compared with nebulized albuterol in one RCT; it showed a decrease in rate of hospitalization but no decrease in the length of hospital stay.11
TABLE 2 Usual Dosages for Quick-Relief Asthma Medications
Usual Dosages for Quick-Relief Asthma Medications
|Medication||Dosage form||Child dosage*|
HFA MDI with spacer: 90 mcg per puff, 200 puffs
1 to 2 puffs every 4 to 6 hours as needed.
Nebulizer solution: 5 mg per mL (0.5 percent), 3.5 mg per 3 mL, 1.25 mg per 3 mL, 0.63 mg per 3 mL
0.05 mg per kg (minimum 1.25 mg, maximum 2.5 mg) in 3 mL of saline every 4 to 6 hours.
MDI with spacer: 18 mcg per puff, 200 puffs
1 to 2 puffs every 6 hours
Nebulizer solution: 0.25 mg per mL (0.025 percent)
0.25 to 0.5 mg every 6 hours
Levalbuterol (R-albuterol, Xopenex)
Nebulizer solution: 0.31 mg per 3 mL, 0.63 mg per 3 mL, 1.25 mg per 3 mL
0.025 mg per kg (minimum 0.63 mg; maximum 1.25 mg) every 4 to 8 hours
2-, 4-, 8-, 16-, and 32-mg tablets
0.25 to 2 mg per kg in the morning or every other day, as needed for control
Short-course “burst”: 1 to 2 mg per kg per day (maximum 60 mg per day) for 3 to 10 days
Same as methylprednisolone
Syrup: 5 mg per 5 mL, 15 mg per 5 mL
1-, 2.5-, 5-, 10-, 20-, and 50-mg tablets
Same as methylprednisolone
Syrup: 5 mg per mL, 5 mg per 5 mL
HFA = hydrofluoroalkane; MDI = metered dose inhaler.
*—Dosages are for children 12 years or younger unless otherwise specified.
Adapted from National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics, 2002. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003. NIH publication no. 02–5074:120–1.
Despite the absence of RCT data, it is common practice to use supplemental oxygen in children with acute asthma exacerbations treated in the emergency department. Low oxygen saturation measured with pulse oximetry has been correlated inversely with the rate of hospitalization.12 However, poor sensitivity and specificity limit the use of oxygen saturation as a single indicator to determine the need for hospitalization.13
The addition of inhaled ipratropium bromide (Atrovent) to each inhalation of a beta2 agonist is more effective than the beta2 agonist alone in children with an acute asthma exacerbation.14 A systematic review of the evidence showed that one hospitalization is prevented for every 12 children treated with this therapy and one for every seven children with a severe exacerbation.15
Oral corticosteroids given early during an acute asthma exacerbation (i.e., within 45 minutes of the onset of symptoms) reduce the likelihood of hospital admission.16 In addition, oral corticosteroids are more effective than inhaled or nebulized corticosteroids in children hospitalized with severe acute asthma.17 Repeated short courses of oral corticosteroids, at a dose of 1 mg per kg per day, in the treatment of acute flares of asthma do not appear to cause any lasting changes in bone metabolism, bone mineralization, or adrenal function.18 There is no evidence that intravenous corticosteroids are any more effective than oral corticosteroids in children with an intact and functioning digestive tract.7
A systematic review of additional studies in the emergency department—including three pediatric studies—demonstrated that inhaled corticosteroids in high doses reduce hospital admission rates in patients with acute asthma. However, there is insufficient evidence that inhaled corticosteroids alone are as effective as systemic steroids.19
Although theophylline is not widely used in the treatment of childhood asthma, there is some improvement of symptoms and lung function with the use of intravenous theophylline in children hospitalized with a severe asthma attack. However, this therapy does not reduce the length of stay or the need for additional bronchodilator treatment, and it is not recommended for routine use.20
Long-Term Medical Therapy
Inhaled corticosteroids are a standard part of maintenance therapy for asthma (Tables 1,3, and4).7 Studies have shown that, as a single agent, inhaled corticosteroids in a medium dosage are more effective than inhaled long-acting beta2 agonists, inhaled nedocromil (Tilade), and leukotriene inhibitors in improving asthma symptoms and lung function in children with mild to moderate asthma.21–23 There also is less use of bronchodilators and oral corticosteroids in patients using maintenance inhaled corticosteroids.24 Some short-term studies have found reduced growth velocity in children using inhaled corticosteroids regularly. However, multiple studies have found no evidence that children treated prophylactically with inhaled corticosteroids fail to reach their full adult height.25,26
TABLE 3 Usual Dosages for Medications Used in the Long-Term Control of Asthma in Children
Usual Dosages for Medications Used in the Long-Term Control of Asthma in Children
Inhaled corticosteroids (see Table 4)
Long-acting inhaled beta2 agonists†
Formoterol (Foradil Aerolizer)
DPI: 12 mcg per single-use capsule
1 capsule every 12 hours
MDI: 21 mcg per puff
1 to 2 puffs every 12 hours
DPI: 50 mcg per blister
1 blister every 12 hours
Fluticasone/salmeterol (Advair Diskus)
DPI: 100, 250, or 500 mcg of fluticasone with 50 mcg of salmeterol
1 inhalation twice daily; dosage depends on severity of asthma
Cromolyn and nedocromil
MDI: 1 mg per puff
1 to 2 puffs 3 to 4 times daily
Nebulizer solution: 20 mg per ampule
1 ampule 3 to 4 times daily
MDI: 1.75 mg per puff
1 to 2 puffs 2 to 4 times daily
4- or 5-mg chewable tablets, 4-mg packet of oral granules, 10-mg tablets
Age 12 to 23 months: 4 mg oral granules at bedtime
Age 2 to 5 years: 4 mg at bedtime
Age 6 to 14 years: 5 mg at bedtime
Older than 14 years: 10 mg at bedtime
10- and 20-mg tablets
Age 7 to 11 years: 20 mg daily in divided doses (i.e., one 10-mg tablet twice daily)
12 years and older: 20 mg twice daily
Liquids, sustained-release tablets, and capsules
Starting dosage is 10 mg per kg per day:
Usual maximums: Age < 1 year: (0.2 x [age in weeks]) + 5 = mg per kg per day Age ≥1 year: 16 mg per kg per day
DPI = dry-powder inhaler; MDI = metered-dose inhaler.
*—Dosages are for children 12 years or younger unless otherwise specified.
†—Should not be used for symptom relief or exacerbations. Use with an inhaled corticosteroid.
‡—Serum monitoring is important (serum concentration of 5 to 15 mcg per mL at steady state).
Adapted from National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis update on selected topics, 2002. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health National Heart, Lung, and Blood Institute, 2003; NIH publication no. 02–5074:133–5.
TABLE 4 Estimated Comparative Daily Dosages of Inhaled Corticosteroids in Children 12 Years and Younger
Estimated Comparative Daily Dosages of Inhaled Corticosteroids in Children 12 Years and Younger
|Agent||Low daily dose||Medium daily dose||High daily dose|
Beclomethasone CFC (Beclovent, Vanceril), 42 or 84 mcg per puff
84 to 336 mcg
336 to 672 mcg
> 672 mcg
Beclomethasone HFA, 40 or 80 mcg per puff
80 to 160 mcg
160 to 320 mcg
> 320 mcg
DPI: 200 mcg per inhalation
100 to 200 mcg
200 to 400 mcg
> 400 mcg
Nebulizer solution: 0.25 or 0.5 mg per ampule
Flunisolide (Aerobid), 250 mcg per puff
500 to 750 mcg
1,000 to 1,250 mcg
> 1,250 mcg
MDI: 44, 110, or 220 mcg per puff
88 to 176 mcg
176 to 440 mcg
> 440 mcg
DPI: 50, 100, or 250 mcg per inhalation
100 to 200 mcg
200 to 400 mcg
> 400 mcg
Triamcinolone acetonide (Azmacort), 100 mcg per puff
400 to 800 mcg
800 to 1,200 mcg
> 1,200 mcg
CFC = chlorofluorocarbon; HFA = hydrofluoroalkane; DPI = dry-powder inhaler; MDI = metered-dose inhaler.
Adapted from National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma: update on selected topics, 2002. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003. NIH publication no. 02–5074:135.
Unlike adults, children whose asthma is inadequately controlled with standard dosages of inhaled corticosteroids have not been shown to benefit from the addition of a long-acting beta2 agonist or from an increase in the dosage of inhaled corticosteroids. In two RCTs,21,27 benefit was demonstrated at three months with the addition of long-acting beta2 agonists, but 12-month follow-up in one of these studies found no difference in objective measures of lung function, symptom scores, or exacerbation rate. One study28 found that doubling the dosage of beclomethasone did not change objective measures of lung function or symptom scores but did result in a significant reduction of growth velocity. Some benefit can be achieved with the addition of oral theophylline, but long-term effects have not been assessed.29 A brief, four-week study of oral montelukast (Singulair) added to standard dosages of inhaled budesonide (Rhinocort Aqua) in children whose asthma was not adequately controlled demonstrated improved lung function and a reduction in the number of days with asthma exacerbations.30
Retrospective observational studies have shown that optimizing the dosage of inhaled corticosteroids provides better control of asthma than oral montelukast.23 However, one open-label, prospective, observational study31 of children with mild asthma found that, in real-world conditions, montelukast and inhaled corticosteroids were equally effective, possibly because of significantly better adherence with oral montelukast therapy. Compared with placebo, oral montelukast reduces total daily use of beta2 agonists, the need for rescue oral corticosteroids, and daytime symptom scores.32,33
NEDOCROMIL AND CROMOLYN
In children, inhaled nedocromil reduces asthma symptom scores, asthma severity, and bronchodilator use and improves lung function compared with placebo.34 However, it is not as effective as inhaled corticosteroids. There is insufficient evidence to recommend prophylactic treatment with inhaled cromolyn (Intal) in children. Although it has been studied for use in children with asthma, it is less effective than inhaled corticosteroids in improving symptoms and lung function.35
LONG-ACTING BETA2 AGONIST
Compared with placebo, salmeterol (Serevent) produces improved lung function in children, but there is conflicting evidence about whether it reduces the use of rescue or short-acting beta2 agonists.36 It was associated with a significant increase in bronchial hyperreactivity compared with inhaled corticosteroids.36 It is not recommended for use as monotherapy in children with asthma. However, limited evidence from a single three-month study27 with 210 patients shows that the combination of a long-acting beta2 agonist and inhaled corticosteroids may increase the number of symptom-free days.
Oral theophylline initially seemed promising in the prophylactic treatment of childhood asthma. When compared with placebo, it significantly increased the mean morning peak expiratory flow rate and reduced the mean number of acute nighttime attacks and doses of bronchodilator used.37 However, it proved to be less promising when its use over one year was compared with the use of inhaled corticosteroids. Although there was no significant difference between theophylline and inhaled corticosteroids in reduction of asthma symptoms, there was an increased use of short-acting beta2 agonists and oral corticosteroids in children receiving theophylline.38 In summary, its use in children cannot be recommended because of the potential for serious side effects, such as cardiac arrhythmias or convulsions, if therapeutic blood levels are exceeded.39
Immunotherapy can be used as an adjunct to standard drug therapy in allergic asthmatic children.40 Sublingual (allergy drops) and injectable (allergy shots) therapies have been shown to reduce the presence of asthma and the overall use of asthma medication.40,41 Standard immunotherapy has a 1.7 to 15 percent reported range of adverse effects, but between 1985 and 1989, there were 17 standard immunotherapy-related deaths reported in the United States.42,43
Educating parents and caregivers of children with asthma to recognize and avoid triggers, and to understand the use of prescribed medications, the proper use of inhalation devices, and the importance of compliance and monitoring, has been shown to improve lung function and decrease school absenteeism and visits to the emergency department.44 Educational programs for the self-management of asthma by children and adolescents have similar outcomes.45 Children with moderate to severe asthma receive the most benefit from educational programs.44,45 The relative effectiveness of the various components of these programs has not been compared directly.44 However, education for children who have received emergency department care for asthma does not reduce subsequent emergency department care, hospitalizations, or unscheduled doctor visits.46
REDUCING ASTHMA TRIGGERS
Asthma triggers include allergens (i.e., dust, mites, pollen), irritants(i.e., smoke, perfumes), physical environment (i.e., exercise, cold air), physiologic triggers (i.e., viral infections), and pharmacologic therapies (i.e., beta blockers).1 Environmental controls such as removal of carpeting in the child’s bedroom, and the use of pillow and mattress covers and air filtration systems have been suggested as ways to reduce asthma symptoms.47 However, recent evidence from better quality studies has shown that dust-mite avoidance measures (using impermeable mattress and pillow covers) did not improve symptoms or reduce medication use in adults with moderate to severe asthma.48 A similar study of children with allergic rhinitis showed no improvement in rhinitis symptoms using impermeable mattress and pillow covers compared with conventional covers.49 The role of avoidance measures as an adjunct to pharmacotherapy or immunotherapy has not been well studied. There is insufficient evidence to recommend for or against the use of air filtration units to reduce allergen levels in an effort to improve asthma symptoms.50
SPACERS VS. NEBULIZERS
The use of a spacer with a metered-dose inhaler for delivery of the bronchodilator has been studied in inpatient, emergency department, and community settings in children as young as 10 months.8,51,52 Metered-dose inhaler delivery of short-acting beta2 agonists has been documented to be as effective as nebulizer delivery in the treatment of an acute asthma exacerbation and at a significantly lower cost.51 In addition, children using a metered-dose inhaler plus a spacer have shorter stays in the emergency department and lower pulse rates than those using a nebulizer.8 When a commercial spacer is unavailable, a device made from a 150-mL paper cup or a 500-mL plastic water bottle has been shown to be just as effective.53 The dosage required for an acute exacerbation has not been well defined and, in studies of children, has ranged from three sprays administered separately to 10 puffs per dose sprayed all at once into the spacer.54,55
Omalizumab and Sublingual Immunotherapy
Several new therapies have been introduced for the treatment of allergic asthma in children. Omalizumab (Xolair) is a recombinant DNA-derived humanized IgG monoclonal antibody that selectively binds to human immunoglobulin E (IgE). It inhibits the binding of IgE to the high-affinity IgE receptor on the surface of mast cells and basophils, limiting release of allergic mediators. Omalizumab is approved for use in children 12 years and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.56,57 In children with moderate to severe asthma, omalizumab reduces the rate of serious asthma exacerbations and the need for physician or emergency department visits and hospitalizations, and improves asthma quality-of-life scores.57 Although this new agent seems promising, its use is likely to be limited because it has an estimated cost of $10,000 per patient per year. Its use may be cost-effective if limited to allergic asthmatics who are poorly controlled on maximal therapy and who are hospitalized five or more times (or for 20 days or longer) per year.58
Sublingual immunotherapy (SLIT) improves asthma symptoms and reduces medication use compared with placebo in children with asthma who are allergic to house dust mites and in children with allergic rhinitis that is related to a variety of common inhalant allergens.41,59 It appears to be safe, with unwanted effects being as low as 9.6 percent and no life-threatening adverse effects reported.60 However, SLIT has not been compared directly with standard immunotherapy. While SLIT is a procedure and therefore is not regulated by the U.S. Food and Drug Administration (FDA), the extracts used for SLIT are FDA-approved for diagnosis and injectable immunotherapy only. Use of FDA-approved allergic extracts for SLIT is an off-label use. Health insurers consider SLIT investigational and do not cover its use.
1. Kemp JP, Kemp JA. Management of asthma in children [published correction appears in Am Fam Physician 2002; 65:386]. Am Fam Physician. 2001;63:1341–8,1353–4.
2. Wahn U. What drives the allergic march? Allergy. 2000;55:591–9.
3. Bergmann RL, Edenharter G, Bergmann KE, Forster J, Bauer CP, Wahn V, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy. 1998;28:965–70.
4. Warner JO, ETAC Study Group . Early treatment of the atopic child. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol. 2001;108:929–37.
5. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109:251–6.
6. Keeley D, McKean M. Asthma and other wheezing disorders of childhood. Clin Evid. 2003;9:287–317.
7. National Asthma Education and Prevention Program. Expert panel report. Guidelines for the diagnosis and management of asthma: update on selected topics, 2002. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2003; NIH publication no. 02–5074.
8. Cates CC, Bara A, Crilly JA, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2003;(3):CD000052.
9. Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA, Rowe BH. Intravenous beta2-agonists for acute asthma in the emergency department. Cochrane Database Syst Rev. 2004;(4):CD002988.
10. Schuh S, Parkin P, Rajan A, Canny G, Healy R, Rieder M, et al. High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics. 1989;83:513–8.
11. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003;143:731–6.
12. Keahey L, Bulloch B, Becker AB, Pollack CV Jr, Clark S, Camargo CA Jr. Initial oxygen saturation as a predictor of admission in children presenting to the emergency department with acute asthma. Ann Emerg Med. 2002;40:300–7.
13. Geelhoed GC, Landau LI, Le Souef PN. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med. 1994;23:1236–41.
14. Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest. 2002;121:1977–87.
15. Plotnick LH, Ducharme FM. Combined inhaled anti-cholinergics and beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2004;(4):CD000060.
16. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev. 2004;(4):CD002178.
17. Smith M, Iqbal S, Elliott TM, Rowe BH. Corticosteroids for hospitalised children with acute asthma. Cochrane Database Syst Rev. 2004;(4):CD002886.
18. Ducharme FM, Chabot G, Polychronakos C, Glorieux F, Mazer B. Safety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density, and adrenal function. Pediatrics. 2003;111:376–83.
19. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2004;(4):CD002308.
20. Mitra A, Bassler D, Ducharme FM. Intravenous aminophylline for acute severe asthma in children over 2 years using inhaled bronchodilators. Cochrane Database Syst Rev. 2004;(4):CD001276.
21. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med. 1997;156(3 pt 1):688–95.
22. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–63.
23. Ducharme FM, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;(4):CD002314.
24. Calpin C, Macarthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systemic review of the literature. J Allergy Clin Immunol. 1997;100:452–7.
25. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 1994;93:967–76.
26. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064–9.
27. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol. 1995;75:423–8.
28. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med. 1998;158:213–9.
29. Nassif EG, Weinberger M, Thompson R, Huntley W. The value of maintenance theophylline in steroid-dependent asthma. N Engl J Med. 1981;304:71–5.
30. Simons FE, Villa JR, Lee BW, Teper AM, Lyttle B, Aristizabal G, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001;138:694–8.
31. Bukstein DA, Luskin AT, Bernstein A. “Real-world” effectiveness of daily controller medicine in children with mild persistent asthma [published correction appears in Ann Allergy Asthma Immunol 2003;91:308]. Ann Allergy Asthma Immunol. 2003;90:543–9.
32. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;279:1181–6.
33. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
34. Armenio L, Baldini G, Bardare M, Boner A, Burgio R, Cavagni G, et al. Double blind, placebo controlled study of nedocromil sodium in asthma. Arch Dis Child. 1993;68:193–7.
35. Tasche MJ, Uijen JH, Bernsen RM, de Jongste JC, van der Wouden JC. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review. Thorax. 2000;55:913–20.
36. Simons FE. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med. 1997;337:1659–65.
37. Pedersen S. Treatment of nocturnal asthma in children with a single dose of sustained-release theophylline taken after supper. Clin Allergy. 1985;15:79–85.
38. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics. 1993;92:64–77.
39. Tsiu SJ, Self TH, Burns R. Theophylline toxicity: update. Ann Allergy. 1990;64(2 pt 2):241–57.
40. Pifferi M, Baldini G, Marrazzini G, Baldini M, Ragazzo V, Pietrobelli A, et al. Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy. 2002;57:785–90.
41. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33:206–10.
42. Hejjaoui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol. 1992;89:925–33.
43. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol. 1993;92(1 pt 1):6–15.
44. Wolf FM, Guevara JP, Grum CM, Clark NM, Cates CJ. Educational interventions for asthma in children. Cochrane Database Syst Rev. 2004;(4):CD000326.
45. Guevara JP, Wolf FM, Grum CM, Clark NM. Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis. BMJ. 2003;326:1308–9.
46. Haby MM, Waters E, Robertson CF, Gibson PG, Ducharme FM. Interventions for educating children who have attended the emergency room for asthma. Cochrane Database Syst Rev. 2004;(4):CD001290.
47. Halken S, Host A, Niklassen U, Hansen LG, Nielsen F, Pedersen S, et al. Effect of mattress and pillow encasings on children with asthma and house dust mite allergy. J Allergy Clin Immunol. 2003:111:169–76.
48. Woodcock A, Forster L, Matthews E, Martin J, Letley L, Vickers M, et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med. 2003;349:225–36.
49. Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med. 2003;349:237–46.
50. Kilburn S, Lasserson TJ, McKean M. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev. 2004;(4):CD002989.
51. Mandelberg A, Tsehori S, Houri S, Gilad E, Morag B, Priel IE. Is nebulized aerosol treatment necessary in the pediatric emergency department?. Chest. 2000;117:1309–13.
52. Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr. 2000;136:497–502.
53. Willemse BW, Toelle BG, Li JS, Shah S, Peat JK. Use of a paper disposable cup as a spacer is effective for the first-aid management of asthma. Respir Med. 2003;97:86–9.
54. Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma [published correction appears in Arch Pediatr Adolesc Med 1995;149:545]. Arch Pediatr Adolesc Med. 1995;149:201–5.
55. Kerem E, Levison H, Schuh S, O’Brodovich H, Reisman J, Bentur L, et al. Efficacy of albuterol administered by nebulizer versus spacer device in children with acute asthma. J Pediatr. 1993;123:313–7.
56. Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87–90.
57. Lemanske RF Jr, Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics. 2002;110:e55.
58. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114:265–9.
59. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2004;(4):CD002893.
60. Pajno GB, Peroni DG, Vita D, Pietrobelli A, Parmiani S, Boner AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs. 2003;5:777–81.
This article is one in a series coordinated by the Department of Family Medicine at the University of Virgnia Health System. Guest editor of the series is David Slawson, M.D.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions